InvestorsHub Logo
Followers 73
Posts 17616
Boards Moderated 0
Alias Born 09/03/2001

Re: TeamTOC post# 23448

Wednesday, 05/12/2021 12:32:35 PM

Wednesday, May 12, 2021 12:32:35 PM

Post# of 28930
From SeekingAlpha:

VBI Vaccines shares rise on late-stage hepatitis B vaccine study data

May 12, 2021 8:34 AM ETVBI Vaccines Inc. (VBIV)By: Aakash Babu, SA News Editor2 Comments
VBI Vaccines (NASDAQ:VBIV) shares rise more than 2% during premarket trading after results from the company's pivotal Phase 3 study of prophylactic 3-antigen hepatitis B (HBV) vaccine candidate in adults were published in The Lancet Infectious Diseases journal.
The study was designed to compare the immunogenicity and safety of 10 µg of VBI’s 3-antigen vaccine candidate to 20 µg of the single-antigen HBV vaccine, Engerix-B.
It enrolled 1,607 adults age ≥ 18, with study participants being randomized 1:1 to receive a 3-dose regimen of either 10 µg of VBI’s 3-antigen vaccine, or 20 µg of Engerix-B, given at Days 0, 28, and 168.
In the study, the seroprotection rate (SPR) – defined as the percent of participants who achieved antibody (anti-HBs) titers above the protective threshold of 10 mIU/mL – in participants ≥ 18 years was 91.4% for VBI’s vaccine compared to 76.5% for Engerix-B at Day 196.
The SPR in adults ≥ 45 years was 89.4% for VBI’s vaccine vs. 73.1% for Engerix-B at Day 196, exceeding the pre-set margins for statistical superiority and clinical superiority.
The safety and tolerability seen in the study were consistent with safety data from previous clinical studies – no safety signals observed in either vaccine arm, and no new safety risks identified, the company said.

https://seekingalpha.com/news/3695215-vbi-vaccines-shares-rise-on-late-stage-hepatitis-b-vaccine-study-data?utm_source=advfn.com&utm_medium=referral
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.